June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Intravitreal bevacizumab for neovascular myopic maculopathy
Author Affiliations & Notes
  • Julio A Urrets-Zavalia
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Dana Martinez
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Eugenia Gonzalez-Castellanos
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Fernanda Barros-Centeno
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Leandro Correa
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Carla D Guantay
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Juan A Dalmagro
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
  • Fernanda Suarez
    CIBICI-CONICET, Faculty of Chemical Sciences, National University of Cordoba, Cordoba, Argentina
  • Evangelina Esposito
    Ophthalmology, Catholic University of Cordoba, Cordoba, Argentina
    The Henry Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • Horacio M Serra
    CIBICI-CONICET, Faculty of Chemical Sciences, National University of Cordoba, Cordoba, Argentina
  • Footnotes
    Commercial Relationships   Julio Urrets-Zavalia, None; Dana Martinez, None; Eugenia Gonzalez-Castellanos, None; Fernanda Barros-Centeno, None; Leandro Correa, None; Carla Guantay, None; Juan Dalmagro, None; Fernanda Suarez, None; Evangelina Esposito, None; Horacio Serra, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Julio A Urrets-Zavalia, Dana Martinez, Eugenia Gonzalez-Castellanos, Fernanda Barros-Centeno, Leandro Correa, Carla D Guantay, Juan A Dalmagro, Fernanda Suarez, Evangelina Esposito, Horacio M Serra; Intravitreal bevacizumab for neovascular myopic maculopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5919.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pathological myopia is observed in about 2% of the general population. Submacular choroidal neovascularization is a leading cause of severe visual loss and blindness in eyes with pathological myopia, affecting 4-11% of those eyes.Purpose: Our aim isT to evaluate the efficacy and safety of intravitreal bevacizumab in the treatment of neovascular myopic maculopathy.

Methods : 22 non-previously treated eyes of 22 consecutive patients with neovascular myopic maculopathy were treated with monthly intravitreal injections of bevacizumab and followed up for 12 months. Changes in BCVA and central macular thickness were evaluated at 12 months of follow-up. All patients were evaluated and treated by the same physician. Wilcoxon test for paired variables, Mann Whitney for independent variables, and Student test for continuous variables, were used for statistical analysis.

Results : Mean age was 54.45± (SD 12.30; (r= 28.00 – 79.00); 7 patients (31.8%) were male and 15 (68.2%) female. Mean spherical equivalent refractive error was -10.89±4.13 (r= -7.00 to -21,00) Mean time elapsed between initial symptoms and the beginning of treatment was 38.68± (SD34.63) days. Patients received a mean of 4.27± (SD 1.86; ( r=2.00 to 9.00) injections. Most injections were performed during the first 6 months of treatment (mean 3.36±1.22 months; SD 1.22; r=1.00 to 6.00). Median BCVA at baseline was 1.00 (P25-75=0.40-1.00) and at 12 months 0.45 (P25-75=0.30-0.70) (p<0.0001). Significant visual improvement was observed between the first (median=1.00, IQR= 0.6) and the third month of treatment (median=0.60, IQR=0.6) (p=0.0002), with no further significant improvement (p=0.09). No ocular or systemic side effects attributable to treatment were observed.

Conclusions : Bevacizumab was effective and safe in our series of myopic patients with neovascular maculopathy, and visual gain remained stable during follow-up.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×